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Objectives: Pulmonary hypertension (PH) has been associated with decreased functional
capacity in patients with advanced idiopathic pulmonary fibrosis (IPF). We aimed to evaluate
the true impact of altered pulmonary hemodynamics on functional capacity in a cohort of
patients with IPF.
Methods: Between January 1990 and December 2007, 124 patients [73M/51F; 111 Caucasians]
with IPF underwent right heart catheterization and 6-min walk test (6MWT). Pulmonary arte-
rial hypertension (PAH) was defined as mPAP 25 and pulmonary artery occlusion pressure
(PAOP) 15 mmHg, and Pre-PH as mPAP> 20 and <25 mmHg with PAOP< 15 mmHg. Demo-
graphic, hemodynamic, spirometric, and 6MWT data were collected.
Results: Fifty four (44%) patients had PH. There were no significant differences between the
PH and the non-PH groups in measures of pulmonary function other than PaO2. Patients with
PH and PAH had significantly lower 6-min walk distance (6MWD) (pZ 0.008 and pZ 0.03
respectively) and distance saturation product (DSP) (pZ 0.002 and pZ 0.006 respectively)
compared to non-PH patients. Mean pulmonary arterial pressure (mPAP) was the best predictor
of 6MWD by multivariate analysis (pZ 0.0006). Increasing mPAP was associated with a statisti-
cally significant decline in 6MWD (pZ 0.02) and DSP (pZ 0.01). Patients with ‘Pre-PH’ had
lower 6MWD compared to patients with mPAP 20 mmHg (pZ 0.07).y for carbon monoxide; DSP, distance saturation product; FVC, forced vital capacity; IPF, idiopathic
distance; PaO2, partial pressure of oxygen; PAOP, pulmonary artery occlusion pressure; mPAP, mean
ean right atrial pressure; sPAP, pulmonary artery systolic pressure; PH, pulmonary hypertension; PAH,
, pulmonary venous hypertension; Pre-PH, pre-pulmonary hypertension (mPAP > 20 and <25 mmHg
ary vascular resistance.
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1614 O.A. Minai et al.Conclusions: Relative to measures of pulmonary function and hypoxia, altered pulmonary
hemodynamics had a greater impact on 6MWD in patients with IPF. Higher mPAP was associated
with more significant exercise impairment. Mild abnormalities in pulmonary hemodynamics (so
called ‘Pre-PH’) were associated with reduced 6MWD.
ª 2012 Elsevier Ltd. All rights reserved.Introduction
Patients with diffuse parenchymal lung diseases have
increased shortness of breath and reduced functional
capacity compared to those without lung diseases. These
restrictions may be a result of compromise in lung function,
hypoxia, and the presence of pulmonary vascular disease.1
Currently, there is no effective medical therapy and
patients with idiopathic pulmonary fibrosis (IPF) have a very
high mortality rate when awaiting lung transplantation.2e5
Major factors associated with an increased risk of death
include older age, and reduction in lung function and
exercise capacity.6e11 Studies have indicated that reduced
6-min walk distance (6MWD)12,13 and desaturation during
the 6-min walk test (6MWT)6,14e16 may also be important
predictors of survival in IPF.
Recently, the presence of pulmonary hypertension (PH)
has been implicated as a factor in reduced survival.4
Reports suggest that the presence of PH may be associ-
ated with reduced functional capacity (as measured by
6MWD); however, these studies have several limitations
including small sample size,4,17 lack of accurate charac-
terization of IPF,12 variability in methodology of 6MWD
measurement,12 and lack of or inadequate hemodynamic
characterization.7,12,13,18 Additionally, due to sample size
and methodologic limitations, previous studies have not
evaluated the influence, if any, of mild abnormalities in
pulmonary hemodynamics (‘Pre-PH’)19 on functional
capacity. Given the impact of PH, it is somewhat surprising
that there is not a single study, of adequate sample size,
evaluating the relative impact of pulmonary function and
well-characterized pulmonary hemodynamics in a cohort of
patients with IPF. The recent ATS Guidelines for the diag-
nosis and management of IPF20 recommend that ‘variables
assessed during the 6MWT warrant additional study’. In the
spirit of this recommendation we performed this study to
evaluate the impact of altered pulmonary hemodynamics
on functional capacity in a larger cohort of patients with
IPF and well-characterized pulmonary hemodynamics.Methods
Subjects
The study was approved by the Cleveland Clinic Institu-
tional Review Board (IRB number 07-001) and data was also
obtained from the Cleveland Clinic Lung Transplant Data-
base (IRB number 06-167). Patient consent was not ob-
tained since this was a retrospective data review and
required no patient contact. We performed a cross-
sectional analysis of a retrospective cohort of consecutivepatients with IPF who were evaluated for lung trans-
plantation at our institution from January 1990 through
December 2007. All adult patients with IPF who underwent
right heart catheterization and a 6MWT as part of their
transplant evaluation were included. The diagnosis of IPF
was established using standard criteria.20,21 A surgical lung
biopsy was not required for confirmation; however, in some
patients the diagnosis was established by this means. To
assure relatedness of the non-invasive tests to the right
heart catheterization, if patients had multiple non-invasive
evaluations, the ones closest to the right heart catheteri-
zation were chosen for analysis.
Data collection
All variables were collected from the Cleveland Clinic lung
transplant database and/or the patients’ medical records.
Pulmonary function testing was performed according to
American Thoracic Society standards.22 Lung volumes were
determined by plethysmography. Predicted normal values
for pulmonary function testing were determined using
a single set of standardized equations.23e25 Arterial blood
gas measurement was performed, with the patient
breathing ambient air. The 6MWTs were conducted in
accordance with the recommendations of the American
Thoracic Society.26 Data pertaining to left ventricular
ejection fraction and right sided pressures were obtained
from transthoracic echocardiograhic testing. Right heart
catheterization was performed with patients at rest in the
supine position.
Definitions
Pulmonary hypertension was defined as a mean pulmonary
arterial pressure (mPAP) 25 mmHg by right heart cathe-
terization.19 Pulmonary arterial hypertension (PAH) was
defined as mPAP 25 mmHg and pulmonary artery occlusion
pressure [PAOP] 15 mmHg, pulmonary venous hyperten-
sion (PVH) was defined as mPAP 25 mmHg and
PAOP> 15 mmHg. Non-PH was defined as mPAP 20 mmHg
and Pre-PH was defined as mPAP> 20 mmHg and <25 mmHg
with PAOP 15 mmHg.19 Distance saturation product (DSP)
was calculated as previously described,14 and was defined as
the product of the final distance walked, in meters, and the
lowest room air oxygen saturation. Pulmonary capacitance
was defined as stroke volume/pulse pressure. It is important
to keep in mind that the term “PAH” as used in this manu-
script simply implies the presence of “pre-capillary pulmo-
nary hypertension” to separate this from PVH or “post-
capillary pulmonary hypertension” based on pulmonary
hemodynamics. This should not be taken to mean that the
6-Min walk test and PH in IPF 1615authors believe that patients designated as “PAH” are
members of World Health Organization Group I PH.Statistical analysis
Analyses were performed to evaluate the impact of
abnormal pulmonary hemodynamics on functional capacity
(as measured by the 6MWT). Continuous measurements
were described as means standard deviations and were
compared using the KruskaleWallis test. Categorical
measurements were summarized using frequencies and
percentages and were compared using Pearson Chi-Square
test. Correlations were calculated between pulmonary
hemodynamic parameters and measures of pulmonary
function, oxygenation, and 6MWD. Patients were divided
into quartiles of mPAP to aid in describing the association of
worsening hemodynamics with measures of pulmonary
function, oxygenation, and 6MWD.
Multivariable regression analysis was used to identify
patient variables associated with 6MWD. All demographic,
hemodynamic, and pulmonary function variables that had at
least 75% values in the dataset were included in the analysis.
Sporadic missing values were imputed using means substitu-
tion. Bootstrap aggregation (bagging) was used for variable
selection,27 with p< 0.07 for entry into the model andTable 1 Demographic and pulmonary function characteristics o
Variable Overall No-P
(mPA
Subjects, N (%) 124 (100) 70 (
Demographics
Age, yrs 55 9.4 55
Male, N (%) 73 (59) 38 (
Caucasian 111 (90) 63 (





BUN/creatinine 21 16 18
Pulmonary function
FVC, % pred 49 15 48
FVC 50% pred,
N (%)
47 (38) 24 (
FEV1, % pred 49 14 49
DLCO, % pred 26 13 28
PaO2, mmHg 58 13 62
6MWT
6MWD, m 348 88 368




DSP, m% 293 80 313
BMI: body mass index; BUN: blood urea nitrogen; FVC % pred: percen
forced expiratory volume in the first second; DLCO % pred: percent
pressure for oxygen; 6MWD: 6-min walk distance; SpO2: oxygen satur
a p-Values comparing no-PH and PH groups.p< 0.05 for variable retention. Variables appearing in at least
50% of bootstrap analyses were considered reliably statisti-
cally significant at p< 0.05 (median rule). SAS 9.1.3 software
(SAS Institute, Cary, North Carolina) was used for all analyses.
Results
Overall population characteristics
A total of 124 adult IPF patients undergoing evaluation for
lung transplantation met criteria and were included in our
analysis (Tables 1 and 2). There were no significant differ-
ences between the PH and the non-PH groups in terms of
demographics or measures of pulmonary function other
than PaO2. Patients with PH had significantly lower 6MWD
and DSP compared with non-PH patients. As expected,
hemodynamics were significantly different between the 2
groups. In addition, patients with PH were significantly
more likely to have a cardiac index< 2 and lower pulmo-
nary capacitance compared to the non-PH group.
Compared to non-PH patients, those with PAH (Table 3)
had lower PaO2, 6MWD, and DSP and were more likely to
have a cardiac index< 2 and reduced pulmonary capaci-
tance. No significant differences were seen in terms of







9.5 54 9.3 0.4
54) 35 (65) 0.2
91) 48 (89) 0.7
4.2 30 7.5 0.09
0.2 0.9 0.3 0.4
5.6 25 24 0.03
13 49 17 0.9
34) 23 (43) 0.3
13 47 15 0.6
13 23 11 0.2
14 52 10 0.001
 81 323 91 0.008
 8 83 8 0.09
2.5 3.6 2.5 0.06
 74 267 80 0.002
t predicted forced vital capacity; FEV1 % pred: percent predicted
predicted diffusion capacity for carbon monoxide; PaO2: partial
ation by pulse oximetry; DSP: distance saturation product.
Table 2 Functional and hemodynamic characteristics of study population (NZ 124).
Variable Overall No-PH (mPAP< 25) PH (mPAP 25) p-Valuea
Subjects, N (%) 124 (100) 70 (56) 54 (44)
Hemodynamics
mRAP, mmHg 5.8 3.9 4.3 2.9 7.8 4 <0.0001
mPAP, mmHg 26.2 10 19 4 35 8 <0.0001
sPAP, mmHg 41.8 15 33 6.4 54 14 <0.0001
Cardiac output, L/min 5.3 1.4 5.4 1.4 5.2 1.4 0.5
Cardiac index, L/min/m2 2.7 0.7 2.9 0.7 2.6 0.6 0.03
Cardiac index< 2, N (%) 10 (10) 2 (4) 8 (18) 0.02
PVR, dyne s/cm5 267 190 182 95 382 220 <0.0001
PAOP, mmHg 10.8 6.3 8.4 3.9 13.9 7.4 <0.0001
Pulse pressure, mmHg 23.4 12 20 5.7 27.5 16 <0.0001
Pulmonary capacitance,b ml/mmHg 3.4 (1.7, 5.2) 3.7 (2.3, 5.7) 2.7 (1.3, 4.2) 0.008
PVR: pulmonary vascular resistance; PAOP: pulmonary artery occlusion pressure.
a p-Values comparing no-PH and PH groups.
b Data shown as 50th percentiles (15th, 85th percentiles) because of distribution of data.
1616 O.A. Minai et al.with PVH, those with PAH had a lower body mass index,
a higher pulmonary vascular resistance, and reduced
pulmonary capacitance. There were no significant differ-
ences in 6MWD or DSP.Association between pulmonary hemodynamics and
functional capacity
There was a significant correlation between 6MWD and
DLCO % predicted, room air PaO2, mRAP, mPAP, sPAP, andTable 3 Patients without PH compared to those with pulmona
(NZ 119).a
Variable No-PH PA
Subjects, N (%) 70 (58.8) 34
Age, years 55.4 9.5 54
BMI, kg/m2 28 4 29
FVC, % pred 48 13 49
FVC 50% pred, N (%) 24 (34) 16
FEV1, % pred 49 13 48
DLCO, % pred 28 13 22
PaO2, mmHg 62.5 14 52
6MWD, m 368 81 32
DSP, m% 313 74 26
mPAP, mmHg 19 4 34
sPAP, mmHg 33 6 52
CI, L/min/m2 2.9 0.7 2.6
CI< 2, N (%) 2 (3) 5 (
PVR, dyne s/cm5 182 95 40
PAOP, mmHg 8 4 10
Pulse pressure, mmHg 20 6 27
Pulmonary capacitance,b ml/mmHg 3.7 (2.3, 5.7) 2.5
BMI: body mass index; FVC % pred: percent predicted forced vital cap
the first second; DLCO % pred: percent predicted diffusion capacity f
min walk distance; DSP: distance saturation product.
a PAOP not available in 5 patients.
b Data shown as 50th percentiles (15th, 85th percentiles) because o
c No-PH vs. PAH by Wilcoxon Rank Sum Test.
d PAH vs. PVH by Wilcoxon Rank Sum Test.PVR (Fig. 1 and Table 1 online supplement). Similarly DSP
was significantly correlated with DLCO % predicted and
room air PaO2 and with mRAP, mPAP, sPAP, and PVR. DSP
showed a small but significant correlation with cardiac
index (rZ 0.2; pZ 0.04) whereas 6MWD did not (rZ 0.1;
pZ 0.1) (Fig. 2 and Table 1 online supplement).
By multivariate analysis, the best predictors of 6MWD
were mPAP and being of Caucasian origin (Table 4). Each
increase of 1 mmHg in mPAP was associated with a 2.6 m
decrease in 6MWD (pZ 0.0006). Patients of White race
walked approximately 56 m further than those of otherry arterial hypertension and pulmonary venous hypertension
H PVH p-Valuec p-Valued
(28.6) 15 (12.6)
.4 9.6 54.8 9 0.6 1
 7 34 8 0.4 0.03
 16 51 20 0.8 0.7
(47) 6 (43) 0.2 0.8
 15 48 16 0.9 0.9
 9 25 11 0.1 0.7
 11 53 10 0.003 0.9
4 92 320 85 0.03 1
5 82 268 73 0.006 0.9
 8 34 5 <0.0001 0.7
 15 56 10 <0.0001 0.09
 0.5 2.5 1.0 0.04 0.7
17) 3 (30) 0.04 0.4
6 200 308 280 <0.0001 0.03
 4 23 5 0.03 <0.0001
 18 33 10 0.001 0.04
(1.2, 3.8) 4.1 (2.7, 4.6) 0.004 0.05
acity; FEV1 % pred: percent predicted forced expiratory volume in
or carbon monoxide; PaO2: partial pressure for oxygen; 6MWD: 6-
f distribution of data.
Figure 1 Correlation of 6MWD with hemodynamics and parameters of pulmonary function.
6-Min walk test and PH in IPF 1617races (pZ 0.03; only marginally confirmed by the
bootstrap).
When analyzing by quartiles of mPAP (Table 5 and
Fig. 3), we found that increasing mPAP was associated with
a statistically significant decline in 6MWD and DSP. The
decline in room air PaO2 did not reach statistical signifi-
cance. Rising mPAP was not associated with significant
changes in demographic variables or measures of pulmo-
nary function.
When patients were divided into those with
PAOP 15 mmHg and those with PAOP> 15 mmHg patients
with PAOP 15 mmHg (Fig. 4) showed a large decrease in
6MWD between those with mPAP 20 mmHg (non-PH) and
those with mPAP> 20 and <25 mmHg (Pre-PH) (pZ 0.07)
and there was very little difference in 6MWD between the
Pre-PH and the mild to moderate PH groups (pZ 0.6).
Patients with PAOP> 15 mmHg did not show similar changes
(Online supplement Tables 2a and 2b).Discussion
Our study advances the current literature regarding 6MWT
and pulmonary hemodynamics in patients with IPF inseveral ways. This is the first study to evaluate the relative
impact of well-characterized pulmonary hemodynamics
and measures of pulmonary function on functional capacity
in patients with IPF. We found that relative to measures of
pulmonary function and hypoxia, altered pulmonary
hemodynamics had a greater impact on 6MWD in these
patients.
The impact of altered pulmonary hemodynamics on
6MWD in IPF has been previously evaluated, and patients
with PH were found to have reduced 6MWD compared to
patients without PH.4,12 However, due to several limita-
tions, including small sample size,4,17 missing pulmonary
function measures, or inadequate hemodynamic charac-
terization,12,18 these studies have been unable to look at
the relative impact of altered pulmonary hemodynamics
and measures of pulmonary function and hypoxia on
functional capacity. The larger studies with 6MWT data in
IPF have either not had access to pulmonary hemodynamic
data13 or had access to incomplete hemodynamic
data.7,12,18 As such, studies have typically concluded that
both factors are altered and relevant to functional
compromise. In our cohort, mPAP was the only measure of
pulmonary hemodynamics or pulmonary function that was
independently associated with 6MWD by multivariate
Figure 2 Correlation of distance saturation product with hemodynamics and parameters of pulmonary function.
1618 O.A. Minai et al.analysis. In addition, previous studies have not looked at
the impact of increasing mPAP on 6MWD largely due to
small sample size and lack of accurate hemodynamic data.
We found that higher mPAP was associated with more
significant exercise impairment in patients with IPF. These
findings together have significant implications for the
contribution of pulmonary vascular disease to functional
limitation in patients with IPF.
Publications evaluating PH in the setting of IPF have
typically utilized the standard definition of PHTable 4 Multivariate predictors of 6-min walk distance in
patients with IPF.
Variable Estimate SE p Bootstrap %
mPAP (mmHg) 2.60 0.73 0.0006 66
Caucasian 55.7 25.2 0.03 47
Interpretation of model: each increase of 1 mmHg is associated
with a decrease of 2.6 m in 6-min walk distance (pZ 0.0006).
Patients of White race walked about 56m further than those of
other races (pZ 0.03; only marginally confirmed by the boot-
strap).(mPAP> 25 mmHg) and have compared those with PH to
those without PH. Recent PH guidelines have modified the
definition of PH to those with mPAP 25 mmHg and have
identified another sub-group of patients as ‘Pre-PH’ (those
with mPAP> 20 mmHg and <25 mmHg19) indicating that
these patients have altered pulmonary hemodynamics but
the true significance of this abnormality requires further
study. In our cohort we have utilized the new standard
definition of PH and have evaluated the impact of mildly
abnormal pulmonary hemodynamics in the ‘Pre-PH’ group.
This is the first study to report that these patients had
lower 6MWD and DSP compared to patients with
mPAP< 20 mmHg indicating that these mild abnormalities
in pulmonary hemodynamics may be having a negative
effect on functional capacity in patients with IPF. This may
be a reflection of the fact that the impact of worsening
pulmonary hemodynamics is a continuous measure and
dichotomous definitions that use artificial cut-off values are
inherently flawed. Just as interestingly, there was only
a minor difference in 6MWD between those with Pre-PH and
those with mild to moderate PH. These findings are
confirmed by the linear negative correlation between
6MWD and DSP and pulmonary hemodynamics including
Table 5 Analysis of study population by quartiles of mPAP.
Variable No. Q1 Q2 Q3 Q4 p
mPAP range (mmHg) <19.83 19.83e24 >24e31 >31
Subjects, N (%) 124 31 (25) 33 (26.6) 29 (23.4) 31 (25)
Age, years 124 57 7 53 11 53 11 56 8 0.6
BMI, kg/m2 124 29 4 28 4 30 7 30 8 0.7
FVC, % pred 124 48 13 50 14 45 13 51 18 0.7
FVC 50% pred, N (%) 10 (32) 13 (39) 11 (38) 13 (43) 0.8
FEV1, % pred 124 49 12 51 14 44 14 50 14 0.3
DLCO, % pred 81 29 13 24 11 27 15 24 12 0.5
PaO2, mmHg 62 61 13 64 17 55 12 53 10 0.07
6MWD, m 124 383 84 354 75 349 81 307 97 0.02
DSP, m% 121 325 77 300 69 289 77 257 83 0.01
sPAP, mmHg 124 28 5 36 5 44 5 60 16 <0.0001
Cardiac index, L/min 98 2.6 0.5 3.1 0.7 2.8 0.5 2.4 0.6 0.005
CI< 2, N (%) 1 (5) 1 (3.4) 0 (0) 8 (31) 0.0008
PVR, dyne s/cm5 94 157 85 204 100 249 95 465 260 <0.0001
PAOP, mmHg 113 7.6 4 8.7 4 13 6 15 8 <0.0001
Pulse pressure, mmHg 124 19 4 21 7 24 6 30 21 <0.0001
Pulmonary capacitance,a ml/mmHg 53 3.7 (2.7, 5.3) 3.6 (2.1, 5.9) 3.7 (1.7, 4.6) 1.8 (1.1, 4.1) 0.02
See text and legend of Table 1.
a Data shown as 50th percentiles (15th, 85th percentiles) because of distribution of data.
6-Min walk test and PH in IPF 1619mPAP, sPAP, and PVR and suggest that the impact of
elevated pulmonary arterial pressure on exercise limitation
is incremental and not determined by an arbitrary
threshold. Larger cohorts of patients with Pre-PH need to
be studied to confirm this finding and to further evaluate its
clinical significance in limiting functional capacity.
Another interesting point is that those with Pre-PH had
a 40 m mean reduction in 6MWD compared to patients with
mPAP 20 mmHg. This difference in 6MWD is close to the
upper threshold of the minimally clinically important
difference for 6MWD recently reported for patients with
IPF (between 24 and 45 m).13 This suggests that the
difference in 6MWD between those with mPAP 20 mmHg
and those with Pre-PH may be clinically significant.
This study strengthens the link between functional
limitation, exertional hypoxia, and pulmonaryFigure 3 Impact of increasing mPAP on 6MWD, distance
saturation product, FVC (% predicted), DLCO (% predicted), and
PaO2 by quartiles of mPAP.hemodynamics in patients with IPF. This is the first study to
report that patients with PH, in the setting of IPF, have
reduced DSP compared to patients without PH, and that
increasing pulmonary arterial pressures are associated
with declining DSP. Several previous studies in IPF have
reported the association between exercise desaturation
and reduced survival6,14e16 independent of pulmonary
function. One previous study has identified a composite
measure (DSP) as a significant predictor of prognosis.14
Unfortunately pulmonary hemodynamics were not
included in that study. Our study indicates that the lower
DSP could have been a surrogate marker for PH in that
population.
The lack of association between pulmonary function
variables such as FVC % predicted and pulmonary hemo-
dynamic abnormalities has been previously reported and
was confirmed in our cohort.6,28 Similar to previous
reports, patients with more hemodynamic abnormalities
did have lower DLCO % predicted compared to patients
without PH; however, this difference did not reach
statistical significance.28 When dividing patients into
quartiles of mPAP it was evident that there was no signif-
icant difference in terms of measures of pulmonary func-
tion between those without PH and those with significant
PH.
Increasing mPAP was associated with higher PAOP but
was also associated with increasing PVR and pulse pressure
and decreasing pulmonary capacitance. Increased pulse
pressure and reduced pulmonary capacitance have been
associated with reduced functional capacity and survival
in patients with pulmonary arterial hypertension.29,30 This
is the first study to show that similar hemodynamic
abnormalities are present in patients with IPF; however,
their significance (if any) requires further study. Even
though patients with PH had lower 6MWD and DSP
compared to patients without PH, it was interesting to
Figure 4 Impact of Pre-PH on 6MWD and distance saturation product among patients with pulmonary artery occlusion
pressure 15 mmHg.
1620 O.A. Minai et al.note that patients with PAOP 15 mmHg had a decline in
6MWD and DSP with increasing mPAP unlike patients with
PAOP> 15 mmHg.
Our study has the limitations of a retrospective, cross-
sectional design. In addition, patients included in the study
had mostly advanced IPF and were being evaluated for lung
transplantation so these results may not be applicable to
the IPF population as a whole.
In conclusion, we found that relative to measures of
pulmonary function and hypoxia, altered pulmonary
hemodynamics had a greater impact on 6MWD in patients
with IPF, that higher mPAP was associated with more
significant exercise impairment, and that mild abnormali-
ties in pulmonary hemodynamics (so called ‘Pre-PH’) were
also associated with a significant reduction in functional
capacity.
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